5 Reasons Why You Must Attend This Event!*

  1. Hear directly from decision making Payers, Hospitals & HTAs about current and emerging market access requirements
  2. Benchmark your product’s market access strategy whether it’s via HTA Evaluation, Tendering or Hospital Procurement
  3. Practice makes perfect - Use our Mock Payer Panels to sharpen your products’ value arguments in front of REAL PAYERS!
  4. Learn something new! With our fresh speaker lineup, you’ll hear current, relevant case studies based on actual market access experiences.
  5. Networking: Make real contact through our unrivalled networking with senior-level industry peers, payers & stakeholders and expert consultancies.

*Only for those looking to improve their MedTech products’ market access.

In the increasingly cost-contained world of medical device market access, Payers (including ministries of health, insurers private & public, hospitals and local governments) are seeking to justify investment in new medical technologies. Health Technology Assessment (HTA) agencies are now widely spreads across Europe assess new technologies and interventions not only on the grounds of clinical effectiveness, but also based on cost-effectiveness, cost-utility and cost-benefit, to ensure the payers’ limited funds are well invested. This HTA and value demonstration requirement has evolved the “commercialisation” landscape of medical devices across the world and this next barrier is one that all medical device companies seeking to gain reimbursement and approval from payers and tendering bodies, need to overcome.

The variety of commercial channels, customers and payers within the medical device space is as diverse as the different business models being used for the different product types (e.g. Imaging Vs Surgical products) and only increases the complexity and specificity of the “value message” which needs to well-delivered, in order to ensure an optimal outcome. This three-day event is the “must-attend” event for all senior directors at medical device companies who are looking to enhance market access for their products.

The first day will feature Europe’s leading payers, HTAs and market access KOLs discussing what they want to see from medical device manufacturers bringing new products to the market and will be a perfect opportunity to engage these key stakeholders. The second day of the event will contrast market access strategies for medical devices in key markets to enable market access and product managers to sequence and prioritise their product launch.

The different stakeholders involved in each market access process and the varying ways to engage them and demonstrate “value” for your technologies will be show from leading companies in the field for you to learn and benchmark from. Participants will leave this event armed with real-life, best practice examples of what is working and not working for your specific product type; what Payers and HTAs consider as essential and “nice to have” information to create “value”; and will have established relationships with the peers from the industry as well as influential decision-makers & KOLs in this sector. We look forward to meeting you in Berlin!

Request agenda here for complete speaker list

Payers, HTA Agencies & Policy Makers

Director General, Communications Networks, Content & Technology
European Commission

Legal & Policy Officer
European Commission

Director, Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member, EUnetHTA

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Head of the Department of Medicines, Therapeutic Appliances & Remedies Product- and Billing Management Division
DAK–Gesundheit, (Leading German statutory health insurance)

Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions

Tender of Pharmaceuticals and Medical devices
Amgros, Pharmaceutical Procurement Service for Regional Authorities, Denmark

Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden

Head of Clinical Engineering Service
Humanitas Research Hospital, Italy

Member
Impact HTA

Member, Joint Committee Vaccination & Immunisation (JCVI) London, UK
Prof. of Pharmacoeconomics, University of Groningen, The Netherlands

 

Industry Experts

Director, Market Access & Economic Policies
MedTech Europe, Belgium

Head of Market Access & Pricing Diabetes Care EMEA
BD, Switzerland

Vice President, Innovation Program Manager
Philips Research

Global Head Market Access, Roche, Switzerland
Board member, MedTech Europe

Vice President Market Access, Latin America
Medtronic, USA

Vice President, Global Reimbursement & Market Access
Second Sight Medical Products, USA

Director, Market Access, EMEA, Canada & LATAM
Edwards Lifesciences, Switzerland

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Global Director, Government Affairs & Public Policy
Terumo, Belgium

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Global Director Scientific Communications | Medical Affairs
Medtronic, France

Vice President Managed Markets
Invitae, USA

Director Market Access and Health Economics, EMEA
Abbott Vascular, Belgium

Program Director
Medtech4Health, Sweden

Global Market Access Director
Straub Medical, Switzerland

Senior International Health Policy Leader
F. Hoffmann-La Roche, Switzerland

International Personalised Reimbursement Model Leader
F. Hoffmann-La Roche, Switzerland

Vice President, Global Market Access
Inspire Medical Systems, USA

Europe Market Access and Pricing Lead PharmaEurope
GSK, UK

Director Payers & Health Economics
Coloplast, Germany

Global Pricing Manager
Philips Healthcare

Sr. Director Marketing & Academy Europe Managing Director Benelux
Arjo, Netherlands

Sr. Manager Segment Marketing
BG Monitoring & Analytics and BG Therapeutic Care
Philips, Germany

Senior Manager Reimbursement & Health Economics
CytoSorbents Europe, Germany

 

Experienced Solution Providers

Managing Director
ValueConnected

Vice President
Boston Healthcare

 

 

 

 

Request agenda here for complete speaker list

Pictures from recent MedTech Access Leaders Forum. Imagine being there...

Global healthcare systems are evolving daily. At a time of increased health economic reform, ageing populations and budget austerity, leaders in medical technology look to achieve optimal market access and commercialization of their products. As payers worldwide demand more value for money on the medical devices they fund, the importance of achieving patient access by demonstrating cost effectiveness and enhanced health outcomes is of the utmost importance. With payers in both developed and developing countries under extreme budgetary pressure, we will provide a platform for attendees to examine how health technologies are assessed, tough decisions are made and how we define “value”. This exclusive forum is the opportunity to meet and network with a broad spectrum of senior representatives who wish to encourage innovation whilst managing a limited budget.

SPEAKER LIST - DAY 1

Director Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Austria
Member EUnetHTA

Senior Scientific Adviser
NICE - National Institute for Health and Care, UK

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Head of the Department of Medicines, Therapeutic Appliances & Remedies Product- and Billing Management Division
DAK–Gesundheit, (Leading German statutory health insurance)

Head of Department of Economic Evidence-based Health Care
Main Association of Austrian Social Insurance Institutions

Director General, Communications Networks, Content & Technology
European Commission

Director, Market Access & Economic Policies
MedTech Europe, Belgium

Head of Market Access & Pricing Diabetes Care EMEA
BD, Switzerland

Global Director, Government Affairs & Public Policy
Terumo, Belgium

Vice President, Innovation Program Manager
Philips Research

 

Medical device firms are increasingly under pressure from payers, HTA agencies, healthcare providers and other stakeholders to provide real evidence of their product’s benefit. Increasingly, especially when a technology is expensive, the CE Mark alone is no longer sufficient to gain market access. Robust health economic evidence demonstrating the clinical and economic value of a device is either becoming mandatory, or at least can be a source or competitive advantage to differentiate apparently similar products. Evidence can still be generated from scientific publications, but on top of this, sophisticated and expensive clinical trials and even real-world studies are now being designed and implemented. Getting the trial design right from the beginning is essential, so that the right research questions are being asked and robust methodologies are used to demonstrate improved health outcomes. Protocols must also be operationally feasible to ensure not just messy data is developed, but real evidence so that payers can gain insights into the value and make better reimbursement decisions. This stream will detail  how clinical, real-world, economic and scientific publication data sources can be integrated to prepare a sophisticated value dossier to demonstrate value to payers and other key stakeholders.

SPEAKER LIST - DAY 2 - STREAM 1

Managing Director
ValueConnected

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Head of Clinical Engineering Service
Humanitas Research Hospital, Italy

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Global Director Scientific Communications | Medical Affairs
Medtronic, France

Vice President, Global Reimbursement & Market Access
Second Sight Medical Products, USA

Vice President, Global Market Access
Inspire Medical Systems, USA

Global Market Access Director
Straub Medical, Switzerland

Global Head Market Access, Roche, Switzerland
Board member, MedTech Europe

Sr. Manager Segment Marketing
BG Monitoring & Analytics and BG Therapeutic Care
Philips, Germany

 

 

 

Medical devices are coming under greater scrutiny by payers and hospital procurement directors than ever before. Manufacturers today are required to understand and quantify the cost savings for hospitals & payers based on the direct & indirect savings their products deliver. Changes to the European directives on public procurement are directly impacting the way medical device companies communicate and market their products via public procurement channels for high-value products. This one-day event will bring together procurement experts from European Policy-level, leading industry associations, hospitals (procurers) and the MedTech industry to join the conversation and to understand better the needs of their strategic partners. It will enable all participants the opportunity to benchmark procurement processes and tender approaches at a regional, local and hospital perspective. Medical device companies will understand in greater detail what their customers are looking for as drivers of value, and what is attractive for them to enhance their tender and public procurement strategy.

SPEAKER LIST - DAY 2 - STREAM 2

Legal & Policy Officer
European Commission

Tender of Pharmaceuticals and Medical devices
Amgros, Pharmaceutical Procurement Service for Regional Authorities, Denmark

Director of Research and Education, Professor in Medical Biophysics
Region Jämtland Härjedalen, Östersund, Sweden

Director, Market Access & Economic Policies
MedTech Europe, Belgium

Program Director
Medtech4Health, Sweden

Director Payers & Health Economics
Coloplast, Germany

Global Pricing Manager
Philips Healthcare

Sr. Director Marketing & Academy Europe Managing Director Benelux
Arjo, Netherlands

As the product nature of personalised medicines and companion diagnostics becomes increasingly complex, so too is the market access process surrounding these essential tests and procedures. These diagnostics bring unique market access & procurement challenged through DRG coding, bundling and procurement for laboratory test service providers. As the cost of these tests increases, so too does the requirement to justify the value and ROI to all necessary stakeholders. For companion diagnostics, partnering and strategic alliances with pharma (if not already vertically integrated) provides a strong market access vector, but achieving this has been proven difficult with only a handful of successful examples to date. As payers, procurers, HMOs and purchasers demand more evidence to justify costs, the challenges surrounding market access have never been greater. This one-day stream will discuss the market access challenges affecting personalised medicine and companion diagnostics globally with case studies of successful launches and cautionary tales of those which were not, to provide benchmarking and learning opportunities for all participants.

SPEAKER LIST - DAY 3 - STREAM A

Global Head Market Access, Roche, Switzerland
Board member, MedTech Europe

Senior International Health Policy Leader
F. Hoffmann-La Roche, Switzerland

International Personalised Reimbursement Model Leader
F. Hoffmann-La Roche, Switzerland

Vice President
Boston Healthcare

Vice President Managed Markets
Invitae, USA

Senior Director, Market Access
Roche Tissue Diagnostics, USA

Member, Joint Committee Vaccination & Immunisation (JCVI) London, UK
Prof. of Pharmacoeconomics, University of Groningen, The Netherlands

Europe Market Access and Pricing Lead PharmaEurope
GSK, UK

 

Surgical device reimbursement & market access now requires more data and value justification than ever before. The good news is that with value adding benefits (minimally invasive procedures; less frequent implant replacement; faster recovery times and greater long-term health benefits), manufacturers have a real opportunity to show what their product can deliver in terms of cost effectiveness to HTAs & Payers. The requirement for existing products to defend their place in the market as well as new products to show true innovation is now a reality. With the data alone now telling the story, it provides large medical device manufacturers the ability to permanently solidify their place in the market and it gives smaller device companies the ability to break into this massive marketplace. This one-day stream will give best practice examples on value demonstration and market access approaches for surgical devices and implantables.

SPEAKER LIST - DAY 3 - STREAM B (AM)

Director, Market Access, EMEA, Canada & LATAM
Edwards Lifesciences, Switzerland

Director Market Access and Health Economics, EMEA
Abbott Vascular, Belgium

Managing Director
ValueConnected

Vice President Market Access, Latin America
Medtronic, USA

Global Market Access Director
Straub Medical, Switzerland

Senior Manager Reimbursement & Health Economics
CytoSorbents Europe, Germany

Before our panel of Subject Matter experts and practitioners, participants will prepare short briefs to demonstrate the value of several fictional case study products to a panel for approval.
As all MedTech market access industry practitioners know, you only get one chance to make a great first impression on payers and procurement decision makers, so this workshop will allow participants to practice their presentations in a safe environment. Assessors will look at: Content, Presentation skills, Style and Evidence Use in order to give constructive feedback.
Participants will be grouped into product specific areas which will enable them to tailor their learnings for their products, including:

- Diagnostic Imaging/Capital Equipment
- Surgical & implantable devices
- E-Health products/SaaMD
- Hospital Consumables (e.g. ostomy, outpatient context, disposables)

Participants will compose and deliver presentations to our panel of Payers/Purchasers to bring the learnings all together.

SPEAKER LIST - DAY 3 - STREAM B (PM)

Workshop Advisors & National Payers:

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

Scientific Coordinator, Agenas HTA Projects
Agenas (Agency for Regional Health Services), Italy

Head of Clinical Engineering Service
Humanitas Research Hospital, Italy

Member
Impact HTA

Senior Director, Head of Health Economics, Market Access & Policy Affairs Europe, Middle-East and Africa
Fresenius Medical Care, Germany

Member, Joint Committee Vaccination & Immunisation (JCVI) London, UK
Prof. of Pharmacoeconomics, University of Groningen, The Netherlands

Device manufacturers & distributors:
Marketing, Market-access, Business Development, Country Managers, Health Economics, Pricing & Reimbursement, Government & Stakeholder Relations, Regulatory Affairs

Stakeholders:
Health Plans & Insurers, Payers, Health Technology Assessors, Hospitals, Health Ministry, Regulatory Agencies, Independent Health Economists, Academics, Physicians and Patient Groups

Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Global and Regional Heads, Independent Academics, Health Economists

The MedTech Access Leaders Forum will also have the PharmAccess Leaders Forum co-located. That event is for senior directors of Market Access at pharma and biotech organisations and will have a specific focus on Specialty Pharma products, Innovative Market Access Agreements and Precision Medicine Market Access. It will also feature a Mock Payer Panel Workshop with Real Payers giving feedback to participants and an additional workshop on Managed Entry Agreements & Risk Sharing approaches. For more information click the banner below:

Event Partners

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Share with Colleagues